Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 13, 2003. The report is a disclosure of a change in the interests of a director in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific director's share transaction.
Material Changes
The material change reported is the acquisition of Ordinary Shares by Director Mr. J D Coombe on February 11, 2003, through the Company's ShareReward Plan. The transaction details are as follows:
- Share Price: £11.25 per Ordinary Share.
- Acquisition Type 1: 12 Ordinary Shares acquired under the partnership element (personal contribution).
- Acquisition Type 2: 12 Ordinary Shares acquired under the matching element (Company contribution).
- Total Shares Acquired: 24 Ordinary Shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the routine disclosure of the director's share purchase.
Key Facts for Investor Verification
- Verify the total number of shares held by Mr. J D Coombe following this transaction.
- Confirm the terms of the ShareReward Plan entered into on October 5, 2001.
- Check for any other director share transactions reported in subsequent filings.